Corcept Therapeutics (CORT)

CORT Endocrinology

BiotechSign Signal Grade

C
Signal Grade
61.8/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Pdufa Date
75
Insider Buying
0
Publications
100
Dilution Risk
10
Clinical Activity
100
Short Interest
30
FDA PDUFA Target Date:2026-12-17 Source

Pipeline Overview

Therapeutic Focus
Endocrinologysrc

Clinical Trial Activity

9
Clinical Trials
(ClinicalTrials.gov aggregate)
2 Phase 1, 7 Phase 2, 1 Phase 3
Trial Phase Breakdown
5
PubMed Publications
1
Catalyst Record

ClinicalTrials.gov aggregate as of 2026-10-12. ClinicalTrials.gov

Dilution Risk

LOW DILUTION RISK
10/100
Dilution Score
15Warrant Risk
15Convertible Risk
20Offering Ability

Dilution score: 10/100 (LOW), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

9.60%
Float Shorted
3.6
Days to Cover
MODERATE
Squeeze Risk
-8.7%
SI Change
DECREASING
Trend
8,540,393
Shares Short

Short interest: 9.6% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Upcoming Catalysts

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Corcept Therapeutics.

Full CORT Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.